← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	1,964	-29	-1%	$145B
2	2 Amgen AMGN $238B	1,518	+44	+3%	$99.2B
3	3 Eli Lilly LLY $1.13T	1,177	-3	-0.3%	$67.1B
4	4 Becton Dickinson BDX $52.5B	984	-13	-1%	$32B
5	5 McKesson MCK $116B	941	-2	-0.2%	$32.6B
6	6 Teva Pharmaceutical Industries Limited TEVA $48.3B	798	-15	-2%	$26.2B
7	7 Conagra Brands CAG $6.87B	694	+8	+1%	$15.8B
8	8 Regeneron Pharmaceuticals REGN $83.1B	555	+13	+2%	$29.6B
9	9 Novo Nordisk NVO $174B	513	-17	-3%	$7.77B
10	10 DaVita DVA $11.9B	482	-20	-4%	$11.2B
11	11 AstraZeneca AZN $261B	451	+53	+13%	$10.9B
12	12 ResMed RMD $33.9B	375	+13	+4%	$5.84B
13	13 Accendra Health ACH $24.9M	286	+3	+1%	$2.03B
14	14 West Pharmaceutical WST $26.8B	280	-9	-3%	$4.93B
15	15 Opko Health OPK $1.19B	270	+25	+10%	$1.35B
16	16 Herbalife HLF $1.53B	232	-10	-4%	$6.27B
17	17 DELISTED CATALENT, INC. CTLT	202	+16	+9%	$3.31B
18	18 Fresenius Medical Care FMS $11.8B	182	+12	+7%	$681M
19	19 Tootsie Roll Industries TR $2.95B	176	+1	+0.6%	$509M
20	20 Medifast MED $137M	165	+12	+8%	$395M
21	21 Dr. Reddy's Laboratories RDY $10.8B	157	0	0%	$1.24B
22	22 MannKind Corp MNKD $987M	151	+4	+3%	$61.4M
23	23 Lexicon Pharmaceuticals LXRX $725M	144	+6	+4%	$2.01B
24	24 Alaunos Therapeutics TCRT $5.54M	140	-14	-9%	$309M
25	25 DELISTED WW International WW	137	-16	-10%	$583M